Dr. David B. Young, D.O.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- At Still University of Health Sciences, College of Osteo Med, Kirksville (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 50
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: At Still University of Health Sciences, College of Osteo Med, Kirksville
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
UT license 7257824-1204 · MI license 5101016473
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Medical groups
- Revere Health PC (410 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 50
- Services billed
- 124
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 34 | 27 |
| New patient office or other outpatient visit, 30-44 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Pleasant Grove, UT | 64 |
| Oxycodone Hcl Other prescribers in Pleasant Grove, UT | 21 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Pleasant Grove, UT | 17 |
| Ibuprofen Other prescribers in Pleasant Grove, UT | 13 |
| Progesterone (progesterone, micronized) Other prescribers in Pleasant Grove, UT | 12 |
| Trazodone Hcl Other prescribers in Pleasant Grove, UT | 12 |
| Myrbetriq (mirabegron) Other prescribers in Pleasant Grove, UT | 11 |
| Ibandronate Sodium Other prescribers in Pleasant Grove, UT | 11 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Pleasant Grove, UT | 11 |
| Sumatriptan Succinate Other prescribers in Pleasant Grove, UT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 15 payments worth $306 in total to this clinician.
| Hologic Sales and Service, LLC | $64.38 |
|---|---|
| Ethicon US, LLC | $60.68 |
| Astellas Pharma US Inc | $59.85 |
| Biogen, Inc. | $43.15 |
| Organon LLC | $18.07 |
| AbbVie Inc. | $16.92 |
| Exeltis, USA Inc. | $16.15 |
| Actelion Pharmaceuticals US, Inc. | $14.78 |
| Food and Beverage | $306 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $21,355 in research payments for these studies, mostly to the institutions running them.
- M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Sev…
AbbVie Inc. - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc. · Active, not recruiting · NCT04333576 - A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or lap
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.